A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer
Novel biomarkers are urgently needed to improve the prediction of clinical outcomes and guide personalized treatment for prostate cancer (PCa) patients. However, the role of N6-methyladenosine (m6A) modifications in PCa initiation and progression remains largely elusive. In our study, we collected b...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-07-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523323000566 |
| _version_ | 1797823388020899840 |
|---|---|
| author | Jianming Lu Jiahong Chen Zhuoyuan Lin Qinwei Liu Chuanfan Zhong Zhouda Cai Zhenyu Jia Weide Zhong Yingke Liang Chao Cai |
| author_facet | Jianming Lu Jiahong Chen Zhuoyuan Lin Qinwei Liu Chuanfan Zhong Zhouda Cai Zhenyu Jia Weide Zhong Yingke Liang Chao Cai |
| author_sort | Jianming Lu |
| collection | DOAJ |
| description | Novel biomarkers are urgently needed to improve the prediction of clinical outcomes and guide personalized treatment for prostate cancer (PCa) patients. However, the role of N6-methyladenosine (m6A) modifications in PCa initiation and progression remains largely elusive. In our study, we collected benign Prostate Hyperplasia (BPH), localized PCa, and metastatic PCa samples from patients and performed methylated RNA immunoprecipitation sequencing (MeRIP-Seq) to map m6A-methylated mRNAs. Furthermore, we developed a prognostic signature based on 239 differentially methylated RNAs and the TCGA-PRAD dataset, which can be used to calculate an m6A-modified mRNA (MMM) score for a PCa patient, validated by independent multi-center cohorts. Our findings revealed that differential m6A modifications were positively correlated with altered expressions of mapped m6A-modified mRNAs. Higher MMM scores were associated with shorter times to biochemical recurrence (BCR) in PCa patients, and the MMM scoring system outperformed three well-established signatures in nine independent validation cohorts, as demonstrated by Kaplan-Meier survival analysis, C-index and ROC. Patients who did not respond to androgen receptor signaling inhibitor (ARSI) therapy and immunotherapy were found to have high MMM scores. Two hub genes, TLE1 and PFKL, were confirmed to have m6A sites through MeRIP-qPCR, and their knockdown promoted PCa cell invasion. Bioinformatics analysis of single-cell databases identified cell types with high transcript abundance levels of these two genes. In summary, our study is the first to perform transcriptome-wide m6A mapping in prostate tissues. The translational potential of a prognostic signature, comprising m6A-methylated mRNAs, in predicting clinical outcomes and therapy responses for PCa patients, is demonstrated. |
| first_indexed | 2024-03-13T10:23:16Z |
| format | Article |
| id | doaj.art-e7a882712efa46fe9f09f31745b6acd7 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-03-13T10:23:16Z |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-e7a882712efa46fe9f09f31745b6acd72023-05-20T04:29:45ZengElsevierTranslational Oncology1936-52332023-07-0133101670A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancerJianming Lu0Jiahong Chen1Zhuoyuan Lin2Qinwei Liu3Chuanfan Zhong4Zhouda Cai5Zhenyu Jia6Weide Zhong7Yingke Liang8Chao Cai9Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University; Guangdong Key Laboratory of Urology; Guangzhou, Guangdong 510230, China; Department of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, ChinaDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, Guangdong 516001, ChinaDepartment of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaDepartment of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University; Guangdong Key Laboratory of Urology; Guangzhou, Guangdong 510230, ChinaDepartment of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, ChinaDepartment of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, ChinaDepartment of Botany and Plant Sciences, University of California, Riverside, CA 92521, USADepartment of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University; Guangdong Key Laboratory of Urology; Guangzhou, Guangdong 510230, China; Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China; Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, ChinaDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, ChinaDepartment of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University; Guangdong Key Laboratory of Urology; Guangzhou, Guangdong 510230, China; Corresponding author.Novel biomarkers are urgently needed to improve the prediction of clinical outcomes and guide personalized treatment for prostate cancer (PCa) patients. However, the role of N6-methyladenosine (m6A) modifications in PCa initiation and progression remains largely elusive. In our study, we collected benign Prostate Hyperplasia (BPH), localized PCa, and metastatic PCa samples from patients and performed methylated RNA immunoprecipitation sequencing (MeRIP-Seq) to map m6A-methylated mRNAs. Furthermore, we developed a prognostic signature based on 239 differentially methylated RNAs and the TCGA-PRAD dataset, which can be used to calculate an m6A-modified mRNA (MMM) score for a PCa patient, validated by independent multi-center cohorts. Our findings revealed that differential m6A modifications were positively correlated with altered expressions of mapped m6A-modified mRNAs. Higher MMM scores were associated with shorter times to biochemical recurrence (BCR) in PCa patients, and the MMM scoring system outperformed three well-established signatures in nine independent validation cohorts, as demonstrated by Kaplan-Meier survival analysis, C-index and ROC. Patients who did not respond to androgen receptor signaling inhibitor (ARSI) therapy and immunotherapy were found to have high MMM scores. Two hub genes, TLE1 and PFKL, were confirmed to have m6A sites through MeRIP-qPCR, and their knockdown promoted PCa cell invasion. Bioinformatics analysis of single-cell databases identified cell types with high transcript abundance levels of these two genes. In summary, our study is the first to perform transcriptome-wide m6A mapping in prostate tissues. The translational potential of a prognostic signature, comprising m6A-methylated mRNAs, in predicting clinical outcomes and therapy responses for PCa patients, is demonstrated.http://www.sciencedirect.com/science/article/pii/S1936523323000566Prostate cancerN6-methyladenosine modified mRNAPrognostic signatureBiochemical recurrenceAndrogen receptor signaling inhibitorImmunotherapy |
| spellingShingle | Jianming Lu Jiahong Chen Zhuoyuan Lin Qinwei Liu Chuanfan Zhong Zhouda Cai Zhenyu Jia Weide Zhong Yingke Liang Chao Cai A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer Translational Oncology Prostate cancer N6-methyladenosine modified mRNA Prognostic signature Biochemical recurrence Androgen receptor signaling inhibitor Immunotherapy |
| title | A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer |
| title_full | A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer |
| title_fullStr | A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer |
| title_full_unstemmed | A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer |
| title_short | A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer |
| title_sort | prognostic signature consisting of n6 methyladenosine modified mrnas demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer |
| topic | Prostate cancer N6-methyladenosine modified mRNA Prognostic signature Biochemical recurrence Androgen receptor signaling inhibitor Immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S1936523323000566 |
| work_keys_str_mv | AT jianminglu aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT jiahongchen aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT zhuoyuanlin aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT qinweiliu aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT chuanfanzhong aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT zhoudacai aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT zhenyujia aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT weidezhong aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT yingkeliang aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT chaocai aprognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT jianminglu prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT jiahongchen prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT zhuoyuanlin prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT qinweiliu prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT chuanfanzhong prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT zhoudacai prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT zhenyujia prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT weidezhong prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT yingkeliang prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer AT chaocai prognosticsignatureconsistingofn6methyladenosinemodifiedmrnasdemonstratesclinicalpotentialinpredictionofbiochemicalrecurrenceandguidanceonprecisiontherapyinprostatecancer |